We’re heading to New York!
We are participating in the 2026 Maxim Growth Summit, October 13-14 in New York City. We look forward to connecting with investors and sharing more about our progress advancing Annamycin.
$MBRX #AML#Oncology#CancerResearch#AcuteMyeloidLeukemia
Hi @elonmusk I guessed by some of your recent content that you have an interest in affordable and accesible drugs as well as health improvement as a whole.
There is a company based in Houston, TX working on an efficient drug that may work for several types of cancers. It is @moleculinbio getting positive results so far developing the first ever non-cardiotoxic anthracycline: Annamycin. It may solve the cumulative heart damage caused by well used and accesible anthracyclines. With your support they will make it faster
Yesterday they announced completion of recruitment for part A (90 patients)
The efficacy signal (MIRACLE unblinded n=45) 🧬🔬MIRACLE trial for R/R AML patients.
@moleculinbio MIRACLE Part A – first unblinding (n=45, full ITT, no exclusions):
CR (1 cycle):
• Annamycin 190 mg/m² + HiDAC → 43%
• Annamycin 230 mg/m² + HiDAC → 36%
• HiDAC control → 12%
CRc: 50% and 57% vs 29% control.
Hard population: ~76% over age 60, many after 7+3 or venetoclax.
That is roughly 3× the control CR rate after a single cycle.
Historical HiDAC salvage CR rates typically sit in the mid-teens.
✅
The iDMC recommended continuing both doses.
Primary source: Moleculin press release June 30, 2026 and OncLive coverage.
Direct PR link:
https://t.co/cO3PUmobA7 (search “Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results”)
The signal is not only numeric: same anthracycline-class mechanism + differentiated cardiac profile.
Not medical or investment advice. Interim data.
#AML #MIRACLE #Annamycin $MBRX
Moleculin announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating AnnAraC for the treatment of adults with R/R AML, with 89 subjects enrolled and an additional subject currently in screening. https://t.co/vjtH9YoPB5 $MBRX
Moleculin announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating AnnAraC for the treatment of adults with R/R AML, with 89 subjects enrolled and an additional subject currently in screening. https://t.co/vjtH9YoPB5 $MBRX
MIRACLE interim (n=45 ITT, June 2026): Annamycin + HiDAC delivered CR rates of 43% and 36% vs 12% for HiDAC control after a single cycle. CRc 50% and 57% vs 29%. @moleculinbio
Same molecule, different cardiac story. Independent expert review across ~90 Annamycin-treated patients in multiple trials: no evidence of cardiotoxicity — including subjects dosed well above the conventional lifetime anthracycline cap.
Venetoclax-failed patients (historically ~13% salvage CR, median OS ~2.4 months) showed blinded CRc of 37% in the later 62-patient snapshot — identical to the overall blinded rate.
Physician survey: likelihood-to-prescribe 6/7. Company peak-revenue framing for 2L AML alone sits in the mid-hundreds of millions. Market cap remains a small-cap clinical-stage number.
The data keep separating safety from every approved anthracycline while the efficacy signal in R/R AML is moving in the right direction. Unblinded Part A readout coming soon.
Hi @elonmusk I guessed by some of your recent content that you have an interest in affordable and accesible drugs as well as health improvement as a whole.
There is a company based in Houston, TX working on an efficient drug that may work for several types of cancers. It is @moleculinbio getting positive results so far developing the first ever non-cardiotoxic anthracycline: Annamycin. It may solve the cumulative heart damage caused by well used and accesible anthracyclines. With your support they will make it faster
The efficacy signal (MIRACLE unblinded n=45) ��🔬MIRACLE trial for R/R AML patients.
@moleculinbio MIRACLE Part A – first unblinding (n=45, full ITT, no exclusions):
CR (1 cycle):
• Annamycin 190 mg/m² + HiDAC → 43%
• Annamycin 230 mg/m² + HiDAC → 36%
• HiDAC control → 12%
CRc: 50% and 57% vs 29% control.
Hard population: ~76% over age 60, many after 7+3 or venetoclax.
That is roughly 3× the control CR rate after a single cycle.
Historical HiDAC salvage CR rates typically sit in the mid-teens.
✅
The iDMC recommended continuing both doses.
Primary source: Moleculin press release June 30, 2026 and OncLive coverage.
Direct PR link:
https://t.co/cO3PUmobA7 (search “Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results”)
The signal is not only numeric: same anthracycline-class mechanism + differentiated cardiac profile.
Not medical or investment advice. Interim data.
#AML #MIRACLE #Annamycin $MBRX
@elonmusk@elonmusk Maybe it is interesting to support small companies like @moleculinbio that is bringing Annmycin. Efficacy, reduced toxicity to 0, and probably much more efficient than other alternatives
@mcuban Maybe it is interesting to support small companies like @moleculinbio that is bringing Annmycin. Efficacy, reduced toxicity to 0, and probably much more efficient than other alternatives
@elonmusk@elonmusk these guys @moleculinbio are developing the first ever non cardiotoxic anthracycline. That is so much needed for cancer patients. They need better funding and stability. It would be peanuts for you more considering the future value of it
Hi @BillAckman I guessed by some of your recent content and enterpreunerships that you have an interest in affordable and accesible drugs as well as health improvement as a whole.
There is a company based in Houston, TX working on an efficient drug that may work for several types of cancers. It is @moleculinbio getting positive results so far developing the first ever non-cardiotoxic anthracycline: Annamycin. It may solve the cumulative heart damage caused by well used and accesible anthracyclines. With your support they will make it faster
The efficacy signal (MIRACLE unblinded n=45) 🧬🔬MIRACLE trial for R/R AML patients.
@moleculinbio MIRACLE Part A – first unblinding (n=45, full ITT, no exclusions):
CR (1 cycle):
• Annamycin 190 mg/m² + HiDAC → 43%
• Annamycin 230 mg/m² + HiDAC → 36%
• HiDAC control → 12%
CRc: 50% and 57% vs 29% control.
Hard population: ~76% over age 60, many after 7+3 or venetoclax.
That is roughly 3× the control CR rate after a single cycle.
Historical HiDAC salvage CR rates typically sit in the mid-teens.
✅
The iDMC recommended continuing both doses.
Primary source: Moleculin press release June 30, 2026 and OncLive coverage.
Direct PR link:
https://t.co/cO3PUmoJpF (search “Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results”)
The signal is not only numeric: same anthracycline-class mechanism + differentiated cardiac profile.
Not medical or investment advice. Interim data.
#AML #MIRACLE #Annamycin $MBRX
Hi @elonmusk I guessed by some of your recent content that you have an interest in affordable and accesible drugs as well as health improvement as a whole.
There is a company based in Houston, TX working on an efficient drug that may work for several types of cancers. It is @moleculinbio getting positive results so far developing the first ever non-cardiotoxic anthracycline: Annamycin. It may solve the cumulative heart damage caused by well used and accesible anthracyclines. With your support they will make it faster
The efficacy signal (MIRACLE unblinded n=45) 🧬🔬MIRACLE trial for R/R AML patients.
@moleculinbio MIRACLE Part A – first unblinding (n=45, full ITT, no exclusions):
CR (1 cycle):
• Annamycin 190 mg/m² + HiDAC → 43%
• Annamycin 230 mg/m² + HiDAC → 36%
• HiDAC control → 12%
CRc: 50% and 57% vs 29% control.
Hard population: ~76% over age 60, many after 7+3 or venetoclax.
That is roughly 3× the control CR rate after a single cycle.
Historical HiDAC salvage CR rates typically sit in the mid-teens.
✅
The iDMC recommended continuing both doses.
Primary source: Moleculin press release June 30, 2026 and OncLive coverage.
Direct PR link:
https://t.co/cO3PUmobA7 (search “Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results”)
The signal is not only numeric: same anthracycline-class mechanism + differentiated cardiac profile.
Not medical or investment advice. Interim data.
#AML #MIRACLE #Annamycin $MBRX
Hi @elonmusk I guessed by some of your recent content that you have an interest in affordable and accesible drugs as well as health improvement as a whole.
There is a company based in Houston, TX working on an efficient drug that may work for several types of cancers. It is @moleculinbio getting positive results so far developing the first ever non-cardiotoxic anthracycline: Annamycin. It may solve the cumulative heart damage caused by well used and accesible anthracyclines. With your support they will make it faster
The efficacy signal (MIRACLE unblinded n=45) 🧬🔬MIRACLE trial for R/R AML patients.
@moleculinbio MIRACLE Part A – first unblinding (n=45, full ITT, no exclusions):
CR (1 cycle):
• Annamycin 190 mg/m² + HiDAC → 43%
• Annamycin 230 mg/m² + HiDAC → 36%
• HiDAC control → 12%
CRc: 50% and 57% vs 29% control.
Hard population: ~76% over age 60, many after 7+3 or venetoclax.
That is roughly 3× the control CR rate after a single cycle.
Historical HiDAC salvage CR rates typically sit in the mid-teens.
✅
The iDMC recommended continuing both doses.
Primary source: Moleculin press release June 30, 2026 and OncLive coverage.
Direct PR link:
https://t.co/cO3PUmobA7 (search “Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results”)
The signal is not only numeric: same anthracycline-class mechanism + differentiated cardiac profile.
Not medical or investment advice. Interim data.
#AML #MIRACLE #Annamycin $MBRX
Hi @elonmusk I guessed by some of your recent content that you have an interest in affordable and accesible drugs as well as health improvement as a whole.
There is a company based in Houston, TX working on an efficient drug that may work for several types of cancers. It is @moleculinbio getting positive results so far developing the first ever non-cardiotoxic anthracycline: Annamycin. It may solve the cumulative heart damage caused by well used and accesible anthracyclines. With your support they will make it faster
The efficacy signal (MIRACLE unblinded n=45) 🧬🔬MIRACLE trial for R/R AML patients.
@moleculinbio MIRACLE Part A – first unblinding (n=45, full ITT, no exclusions):
CR (1 cycle):
• Annamycin 190 mg/m² + HiDAC → 43%
• Annamycin 230 mg/m² + HiDAC → 36%
• HiDAC control → 12%
CRc: 50% and 57% vs 29% control.
Hard population: ~76% over age 60, many after 7+3 or venetoclax.
That is roughly 3× the control CR rate after a single cycle.
Historical HiDAC salvage CR rates typically sit in the mid-teens.
✅
The iDMC recommended continuing both doses.
Primary source: Moleculin press release June 30, 2026 and OncLive coverage.
Direct PR link:
https://t.co/cO3PUmoJpF (search “Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results”)
The signal is not only numeric: same anthracycline-class mechanism + differentiated cardiac profile.
Not medical or investment advice. Interim data.
#AML #MIRACLE #Annamycin $MBRX
Moleculin today announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposomal Annamycin technology. Read more: https://t.co/MHadyrUG6r $MBRX
Hi @mcuban I guessed by some of your recent content and enterpreunerships that you have an interest in affordable and accesible drugs as well as health improvement as a whole.
There is a company based in Houston, TX working on an efficient drug that may work for several types of cancers. It is @moleculinbio getting positive results so far developing the first ever non-cardiotoxic anthracycline: Annamycin. It may solve the cumulative heart damage caused by well used and accesible anthracyclines. With your support they will make it faster
The efficacy signal (MIRACLE unblinded n=45) 🧬🔬MIRACLE trial for R/R AML patients.
@moleculinbio MIRACLE Part A – first unblinding (n=45, full ITT, no exclusions):
CR (1 cycle):
• Annamycin 190 mg/m² + HiDAC → 43%
• Annamycin 230 mg/m² + HiDAC → 36%
• HiDAC control → 12%
CRc: 50% and 57% vs 29% control.
Hard population: ~76% over age 60, many after 7+3 or venetoclax.
That is roughly 3× the control CR rate after a single cycle.
Historical HiDAC salvage CR rates typically sit in the mid-teens.
✅
The iDMC recommended continuing both doses.
Primary source: Moleculin press release June 30, 2026 and OncLive coverage.
Direct PR link:
https://t.co/cO3PUmobA7 (search “Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results”)
The signal is not only numeric: same anthracycline-class mechanism + differentiated cardiac profile.
Not medical or investment advice. Interim data.
#AML #MIRACLE #Annamycin $MBRX
Hi @elonmusk I guessed by some of your recent content that you have an interest in affordable and accesible drugs as well as health improvement as a whole.
There is a company based in Houston, TX working on an efficient drug that may work for several types of cancers. It is @moleculinbio getting positive results so far developing the first ever non-cardiotoxic anthracycline: Annamycin. It may solve the cumulative heart damage caused by well used and accesible anthracyclines. With your support they will make it faster
The efficacy signal (MIRACLE unblinded n=45) 🧬🔬MIRACLE trial for R/R AML patients.
@moleculinbio MIRACLE Part A – first unblinding (n=45, full ITT, no exclusions):
CR (1 cycle):
• Annamycin 190 mg/m² + HiDAC → 43%
• Annamycin 230 mg/m² + HiDAC → 36%
• HiDAC control → 12%
CRc: 50% and 57% vs 29% control.
Hard population: ~76% over age 60, many after 7+3 or venetoclax.
That is roughly 3× the control CR rate after a single cycle.
Historical HiDAC salvage CR rates typically sit in the mid-teens.
✅
The iDMC recommended continuing both doses.
Primary source: Moleculin press release June 30, 2026 and OncLive coverage.
Direct PR link:
https://t.co/cO3PUmobA7 (search “Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results”)
The signal is not only numeric: same anthracycline-class mechanism + differentiated cardiac profile.
Not medical or investment advice. Interim data.
#AML #MIRACLE #Annamycin $MBRX